What question did this study set out to answer?

To review novel pharmacologic agents, procedural interventions, and enhanced diagnostic tools for stroke prevention in patients with atrial fibrillation.

January 1, 2012Cerebrovascular DiseasesOpen Access

New Frontiers for Stroke Prevention in Atrial Fibrillation

View Full Paper

Ask AI

Bookmark

Why the study?

What are the current and emerging pharmacologic and nonpharmacologic options for stroke prevention in patients with atrial fibrillation?

Key Points

To review novel pharmacologic agents, procedural interventions, and enhanced diagnostic tools for stroke prevention in patients with atrial fibrillation.
Synthesis of clinical trial data evaluating target-specific oral anticoagulants against traditional warfarin therapy.
Evaluation of percutaneous and surgical left atrial appendage occlusion techniques.
Assessment of advanced diagnostic monitoring modalities for identifying paroxysmal atrial fibrillation.
Target-specific agents including dabigatran, rivaroxaban, and apixaban mitigate standard warfarin limitations by eliminating routine international normalized ratio monitoring and extensive interactions.
Percutaneous and surgical occlusion of the left atrial appendage provides a localized, nonpharmacologic alternative for thrombus prevention in high-risk patients.
Sensitive diagnostic devices improve detection rates of paroxysmal atrial fibrillation, enabling earlier implementation of stroke preventive therapies.

Structured PICO

What are the current and emerging pharmacologic and nonpharmacologic options for stroke prevention in patients with atrial fibrillation?

Population

Patients with atrial fibrillation

Intervention

Pharmacologic alternatives to warfarin (dabigatran, rivaroxaban, apixaban) and nonpharmacologic approaches (left atrial appendage occlusion/ligation)

Comparator

Warfarin

Outcome

Stroke prevention

This review highlights emerging alternatives to warfarin, including direct oral anticoagulants and left atrial appendage occlusion, for stroke prevention in atrial fibrillation.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Expands options beyond warfarin for AF stroke prevention; leaves open optimal patient selection and comparative outcomes.

Cite This Study

Prasad et al. (2012) studied this question.

synapsesocial.com/papers/6a702c73e36a167817e1eaa3 https://doi.org/10.1159/000334979

Topics

Atrial fibrillation Anticoagulation in AF Persistent AF management Dual antiplatelet therapy

View Full Paper

Ask AI

Bookmark

New Frontiers for Stroke Prevention in Atrial Fibrillation

Key Points

Structured PICO

Discussion

Implication

Cite This Study

Topics

New Frontiers for Stroke Prevention in Atrial Fibrillation

Key Points

Structured PICO

Discussion

Implication

Cite This Study

Also Consider

Topics

Also Consider